Craig B. Thompson
克雷格·汤普森
MD
President and CEO; Professor of Medicine主席兼首席执行官；医学教授
👥Biography 个人简介
Craig B. Thompson, MD is President and CEO of Memorial Sloan Kettering Cancer Center. A pioneer in cancer metabolism, he demonstrated how oncogenic PI3K/Akt/mTOR signaling drives nutrient uptake and anabolic growth. His work on IDH1/IDH2 mutations and 2-hydroxyglutarate production has fundamentally reshaped understanding of epigenetic dysregulation in cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PI3K/Akt/mTOR Metabolic Signaling
Established that growth-factor receptor and PI3K pathway activation drives glucose and glutamine uptake independent of bioenergetic demand, reframing cancer metabolism as a consequence of oncogenic signaling.
IDH Mutations and 2-HG
Co-discovered that IDH1/IDH2 gain-of-function mutations produce the oncometabolite 2-hydroxyglutarate, linking metabolic alterations to epigenetic reprogramming in glioma and AML.
Representative Works 代表性著作
The metabolic basis of tumor cell proliferation
Science (2009)
Landmark review linking oncogene-driven nutrient uptake to cellular biomass production and tumor growth.
IDH1 and IDH2 mutations in gliomas
New England Journal of Medicine (2009)
Identified neomorphic IDH mutations producing 2-HG as a driver of gliomagenesis.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Faisal Mahmood
Brigham and Women's Hospital; Harvard Medical School
Kun-Hsing Yu
Harvard Medical School; Brigham and Women's Hospital
Ziad Obermeyer
University of California, Berkeley; UC San Francisco
Andrew H. Beck
PathAI; Harvard Medical School (formerly)
关注 克雷格·汤普森 的研究动态
Follow Craig B. Thompson's research updates
留下邮箱，当我们发布与 Craig B. Thompson（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment